HK1196609A1 - 氨基喹唑啉類衍生物及其鹽和使用方法 - Google Patents
氨基喹唑啉類衍生物及其鹽和使用方法Info
- Publication number
- HK1196609A1 HK1196609A1 HK14110000.1A HK14110000A HK1196609A1 HK 1196609 A1 HK1196609 A1 HK 1196609A1 HK 14110000 A HK14110000 A HK 14110000A HK 1196609 A1 HK1196609 A1 HK 1196609A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- salts
- methods
- aminoquinazoline derivatives
- aminoquinazoline
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110359739 | 2011-11-14 | ||
PCT/CN2012/001545 WO2013071697A1 (en) | 2011-11-14 | 2012-11-14 | Aminoquinazoline derivatives and their salts and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1196609A1 true HK1196609A1 (zh) | 2014-12-19 |
Family
ID=48310576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14110000.1A HK1196609A1 (zh) | 2011-11-14 | 2014-10-07 | 氨基喹唑啉類衍生物及其鹽和使用方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US9181277B2 (zh) |
EP (1) | EP2780342B1 (zh) |
JP (1) | JP6126613B2 (zh) |
KR (1) | KR101965271B1 (zh) |
CN (1) | CN103102344B (zh) |
AR (1) | AR092289A1 (zh) |
AU (1) | AU2012339499B2 (zh) |
CA (1) | CA2851151C (zh) |
ES (1) | ES2580481T3 (zh) |
HK (1) | HK1196609A1 (zh) |
TW (1) | TWI577671B (zh) |
WO (1) | WO2013071697A1 (zh) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2796451B1 (en) * | 2011-12-20 | 2018-08-01 | Wei Qian | Heterocycle amido alkyloxy substituted quinazoline derivative and use thereof |
EP2935240A1 (en) | 2012-12-21 | 2015-10-28 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
PT2935222T (pt) | 2012-12-21 | 2018-12-10 | Epizyme Inc | Inibidores de prmt5 e seus usos |
US8940726B2 (en) | 2012-12-21 | 2015-01-27 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
EP2935241A1 (en) | 2012-12-21 | 2015-10-28 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
CA2894157A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
AU2014216178B2 (en) | 2013-02-15 | 2018-06-28 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
BR112015020139A2 (pt) | 2013-02-20 | 2017-07-18 | Kala Pharmaceuticals Inc | compostos terapêuticos e usos dos mesmos |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
CN104513237A (zh) * | 2013-09-30 | 2015-04-15 | 重庆药友制药有限责任公司 | 一种制备n-甲基莫西沙星的新方法 |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
KR20160099084A (ko) | 2013-11-01 | 2016-08-19 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정질 형태 및 그의 용도 |
CN104744446B (zh) * | 2013-12-30 | 2019-06-25 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
EP3160466A4 (en) * | 2014-06-25 | 2017-12-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
KR102378648B1 (ko) * | 2014-07-24 | 2022-03-28 | 베링거 인겔하임 인터내셔날 게엠베하 | 알도스테론 신타아제 억제제 |
CA2953572A1 (en) | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
KR20170090422A (ko) | 2014-10-31 | 2017-08-07 | 인디비어 유케이 리미티드 | 도파민 d3 수용체 길항제 화합물 |
US20180050993A1 (en) * | 2015-02-03 | 2018-02-22 | Trillium Therapeutics Inc. | Novel fluorinated derivatives as egfr inhibitors useful for treating cancers |
CN106146412B (zh) * | 2015-03-31 | 2019-05-24 | 广州市恒诺康医药科技有限公司 | 喹唑啉衍生物及其制备方法和应用 |
US10308658B2 (en) * | 2015-10-19 | 2019-06-04 | Sunshine Lake Pharma Co., Ltd. | Salt of EGFR inhibitor, crystalline form and uses thereof |
CN105294717B (zh) * | 2015-11-18 | 2017-12-22 | 乳源瑶族自治县大众药品贸易有限公司 | 一种egfr抑制剂的盐、晶型及其用途 |
CN105294719B (zh) * | 2015-11-18 | 2017-12-22 | 乳源瑶族自治县大众药品贸易有限公司 | 一种氨基喹唑啉类衍生物的二对甲苯磺酸盐及其晶型 |
CN105294715B (zh) * | 2015-11-18 | 2017-12-22 | 乳源瑶族自治县大众药品贸易有限公司 | 一种氨基喹唑啉类衍生物的富马酸盐及其晶型 |
CN105461729B (zh) * | 2015-11-18 | 2017-12-05 | 乳源瑶族自治县大众药品贸易有限公司 | 一种egfr抑制剂的盐、晶型及其用途 |
CN105294718B (zh) * | 2015-11-18 | 2018-01-23 | 乳源瑶族自治县大众药品贸易有限公司 | 一种氨基喹唑啉类衍生物的马来酸盐及其晶型 |
CN105294716B (zh) * | 2015-11-18 | 2017-12-22 | 乳源瑶族自治县大众药品贸易有限公司 | 一种氨基喹唑啉类衍生物的二水杨酸盐及其晶型 |
EP3241830A1 (de) | 2016-05-04 | 2017-11-08 | Bayer CropScience Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
AU2017324716B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CN109688818A (zh) | 2016-09-08 | 2019-04-26 | 卡拉制药公司 | 治疗化合物的晶型及其用途 |
EP3509422A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
CN107793420A (zh) * | 2017-12-11 | 2018-03-13 | 康化(上海)新药研发有限公司 | 一种3,4‑二氢‑2H‑吡喃[3,2‑b]吡啶的合成方法 |
JP2021512959A (ja) | 2018-02-06 | 2021-05-20 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Jiangsu Hengrui Medicine Co., Ltd. | ピラゾロ[1,5−a][1,3,5]トリアジン−2−アミン誘導体、その製造法、およびその医薬用途 |
CN113549063B (zh) * | 2020-04-23 | 2024-04-05 | 南京药石科技股份有限公司 | 一种光学异构的八氢-2H-吡咯并[3,4-c]吡啶-2-羧酸叔丁酯的制备方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
US20060063752A1 (en) | 2000-03-14 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
US6617329B2 (en) * | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
DE10042059A1 (de) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
DE60327323D1 (de) | 2002-07-09 | 2009-06-04 | Astrazeneca Ab | Chinazoline derivative und ihre anwendung in der krebsbehandlung |
AU2003249212C1 (en) | 2002-07-15 | 2011-10-27 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
US7560558B2 (en) | 2002-08-23 | 2009-07-14 | Kirin Beer Kabushiki Kaisha | Compound having TGFβ inhibitory activity and medicinal composition containing the same |
CN100354278C (zh) * | 2002-11-04 | 2007-12-12 | 阿斯利康(瑞典)有限公司 | 作为src酪氨酸激酶抑制剂的喹唑啉衍生物 |
PT1562955E (pt) * | 2002-11-04 | 2008-05-05 | Astrazeneca Ab | Derivados de quinazolina como inibidores da scr tirosina-cinase |
GB0226434D0 (en) * | 2002-11-13 | 2002-12-18 | Astrazeneca Ab | Combination product |
RU2005135337A (ru) * | 2003-04-16 | 2006-06-10 | Астразенека Аб (Se) | Производные хиназолина для лечения злокачественного новообразования |
WO2004108707A1 (en) * | 2003-06-05 | 2004-12-16 | Astrazeneca Ab | Pyridazinil quinazoline derivatives for use in the treatment of tumours |
WO2004108710A1 (en) * | 2003-06-05 | 2004-12-16 | Astrazeneca Ab | 4-pyrimidinyl quinazoline derivatives for use in the treatment of tumours |
WO2004108711A1 (en) * | 2003-06-05 | 2004-12-16 | Astrazeneca Ab | Pyrazinil quinazoline derivatives for use in the treatment of tumours |
GB0318423D0 (en) * | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
RU2370494C2 (ru) | 2003-09-19 | 2009-10-20 | Астразенека Аб | Производные хиназолина |
GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
ES2371383T3 (es) | 2003-09-26 | 2011-12-30 | Exelixis, Inc. | N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida para el tratamiento del cáncer. |
WO2006081741A1 (fr) | 2005-02-05 | 2006-08-10 | Piaoyang Sun | Dérivés de quinazoline ou leurs sels de qualité pharmaceutique, synthèse et applications médicales desdites substances |
MX2010007852A (es) * | 2008-01-18 | 2010-11-30 | Natco Pharma Ltd | Derivados de 6,7-dialcoxi-quinazolina utiles para el tratamiento de trastornos relacionados con cancer. |
US8426430B2 (en) | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
CN101619043B (zh) * | 2008-06-30 | 2013-06-05 | 和记黄埔医药(上海)有限公司 | 喹唑啉衍生物及其医药用途 |
CN101367793B (zh) | 2008-09-26 | 2013-09-11 | 中国科学院广州生物医药与健康研究院 | 一种具有抗肿瘤活性的氨基喹唑啉衍生物及其盐类 |
CN102686581B (zh) | 2009-12-21 | 2015-08-26 | 张强 | 喹唑啉衍生物 |
CN101836992A (zh) * | 2010-05-27 | 2010-09-22 | 东南大学 | 4-苯并噻酚氨基喹唑啉衍生物在制备***药物方面的应用 |
WO2012000182A1 (en) | 2010-06-30 | 2012-01-05 | Hutchison Medipharma Limited | Quinazoline compounds |
CN102452988B (zh) | 2010-10-27 | 2016-01-27 | 中国科学院化学研究所 | 一种喹唑啉衍生物及其制备方法 |
EP2796451B1 (en) * | 2011-12-20 | 2018-08-01 | Wei Qian | Heterocycle amido alkyloxy substituted quinazoline derivative and use thereof |
-
2012
- 2012-11-13 TW TW101142230A patent/TWI577671B/zh active
- 2012-11-13 AR ARP120104278A patent/AR092289A1/es active IP Right Grant
- 2012-11-14 US US14/346,741 patent/US9181277B2/en active Active
- 2012-11-14 JP JP2014540291A patent/JP6126613B2/ja active Active
- 2012-11-14 ES ES12850573.2T patent/ES2580481T3/es active Active
- 2012-11-14 KR KR1020147015953A patent/KR101965271B1/ko active IP Right Grant
- 2012-11-14 WO PCT/CN2012/001545 patent/WO2013071697A1/en active Application Filing
- 2012-11-14 CN CN201210455452.XA patent/CN103102344B/zh active Active
- 2012-11-14 EP EP12850573.2A patent/EP2780342B1/en active Active
- 2012-11-14 AU AU2012339499A patent/AU2012339499B2/en active Active
- 2012-11-14 CA CA2851151A patent/CA2851151C/en active Active
-
2014
- 2014-10-07 HK HK14110000.1A patent/HK1196609A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU2012339499A1 (en) | 2014-06-05 |
CA2851151C (en) | 2017-09-12 |
JP2014534975A (ja) | 2014-12-25 |
TW201319055A (zh) | 2013-05-16 |
AU2012339499B2 (en) | 2015-09-10 |
KR20140093271A (ko) | 2014-07-25 |
EP2780342B1 (en) | 2016-06-01 |
CN103102344B (zh) | 2015-10-14 |
US20140228361A1 (en) | 2014-08-14 |
WO2013071697A1 (en) | 2013-05-23 |
EP2780342A4 (en) | 2015-04-08 |
EP2780342A1 (en) | 2014-09-24 |
CN103102344A (zh) | 2013-05-15 |
US9181277B2 (en) | 2015-11-10 |
AR092289A1 (es) | 2015-04-15 |
KR101965271B1 (ko) | 2019-04-03 |
TWI577671B (zh) | 2017-04-11 |
JP6126613B2 (ja) | 2017-05-10 |
CA2851151A1 (en) | 2013-05-23 |
ES2580481T3 (es) | 2016-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1196609A1 (zh) | 氨基喹唑啉類衍生物及其鹽和使用方法 | |
HRP20181628T1 (hr) | Spojevi i postupci za njihovu upotrebu | |
HK1198433A1 (zh) | -酰基二肽衍生物及其應用 | |
HK1212977A1 (zh) | 苯達莫司汀衍生物及其使用方法 | |
SI2683731T1 (sl) | C4-monometil triterpenoidni derivati in postopki njihove uporabe | |
ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
EP2536283A4 (en) | PHENYLHETEROARYL DERIVATIVES AND USE METHOD THEREFOR | |
IL228072A0 (en) | Alkyl-substituted quinazoline compounds and methods of use | |
EP2548859A4 (en) | PREPARATION OF METHYL-D3-AMINE AND SALTS THEREOF | |
AP3268A (en) | Co-crystals and salts of CCR3-inhibitors | |
ZA201209666B (en) | Salts and polymorhs of dexrabeprazole | |
EP2709999A4 (en) | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | |
EP2766356A4 (en) | QUINAZOLINE DERIVATIVES AS INHIBITORS OF KINASES AND METHODS OF USE THEREOF | |
ZA201207945B (en) | Salts of dexlansoprazole and their preparation | |
HK1205695A1 (zh) | 副粘病毒和使用方法 | |
PT2709584T (pt) | Utilização sensorial dos derivados de 6-ciclopentilideno-hexano | |
EP2699539A4 (en) | CYCLOPROPYLATED DERIVATIVES AND METHODS OF USE |